| 產(chǎn)品名稱 | Kasumi-4 |
|---|---|
| 商品貨號 | B237910 |
| Organism | Homo sapiens, human |
| Tissue | peripheral blood |
| Product Format | frozen |
| Morphology | myeloblast |
| Culture Properties | suspension |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | chronic myeloblastic leukemia (CML) |
| Age | 6 years |
| Gender | female |
| Ethnicity | Japanese |
| Applications | This cell line is useful for studying the mechanisms of leukaemogenesis involving a three-way translocation containing the Philadelphia (Ph) chromosome and an inv(3)(q21q26). |
| Storage Conditions | liquid nitrogen vapor phase |
| Karyotype | 46, XX; t(9;22;11) (q34;q11;q13), inv(3)(q21q26) |
| Images |  |
| Derivation | Kasumi-4 was established from the peripheral blood of a 6-year-old girl suffering from chronic myelogenous leukemia (CML) in blast crisis. |
| Clinical Data | female
Japanese
6 years |
| Comments | A high level of expression of the EVI1 gene was observed [PubMed; 8611478]. The cells are negative for expression of the PRDM16 (MEL1) gene. Ref |
| Complete Growth Medium | RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate supplemented with 10 ng/ml human recombinant granulocyte macrophage colony stimulating factor (GM-CSF) and 20% fetal bovine serum
|
| Subculturing | Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 x 105 viable cells/mL.
Interval: Maintain cultures at a cell concentration between 3 x 105 and 3 x 106 viable cells/mL. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile | Amelogenin: X CSF1PO: 10,12 D13S317: 10,12 D16S539: 9,13 D5S818: 11,12 D7S820: 8,10 THO1: 8,9 TPOX: 8,11 vWA: 16,18 |
| Population Doubling Time | 55 to 60 hours |
| Name of Depositor | H Asou |
| Deposited As | human |
| Year of Origin | July 9, 1993 |
| References | Mochizuki N, et al. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood 96: 3209-3214, 2000. PubMed: 11050005 Suzukawa K, et al. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26). Genomics 42: 356-360, 1997. PubMed: 9192861 Suzukawa K, et al. Activation of EVI1 transcripts with chromosomal translocation joining the TCRVbeta locus and the EVI1 gene in human acute undifferentiated leukemia cell line (Kasumi-3) with a complex translocation of der(3)t(3;7;8). Leukemia 13: 1359-1366, 1999. PubMed: 10482986 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
Mochizuki N, et al. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood 96: 3209-3214, 2000. PubMed: 11050005